We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
5
Oct 2026
Idiopathic short stature (ISS) describes children whose height is substantially below the expected range for their age and sex without any identifiable medical cause.
5
Oct 2026
Bloodstream infections are a persistent threat to hospitalized patients, and those caused by fungi are particularly dangerous. Candida species are responsible for most invasive fungal infections worldwide and rank among the leading causes of hospital-acquired bloodstream infections overall.
5
Oct 2026
Aston University School of Optometry and Globe Biomedical have announced a research collaboration for Blink Frames, Globe Biomedical's smart eyewear platform, which continually monitors a patient's eyes via normal-looking spectacle frames.
5
Oct 2026
Skin cancer is a global health challenge, with nearly 1.5 million new cases diagnosed in 2024 according to World Health Organization (WHO) data. In response, the University of Alicante (UA) and the Sant Joan d'Alacant University Hospital have collaborated to launch MEL-IA (MobilE skin Lesion dIAgnosis), an artificial intelligence system designed to automate the classification of skin lesions.